Erratum: A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent (PLoS ONE (2018) 13:6 (e0199130) DOI: 10.1371/journal.pone.0199130)

Abstract

There is information missing from the Competing Interests statement. The correct Competing Interests statement is as follows: N.A. was a consultant for Cepheid, and has licensed a bio-marker for early detection of pancreas cancer to Cepheid (PATENT # 10167513). N.A also has grant funding from Astex Pharmaceuticals (GRANT # 120039). N.A. has served as a consultant to Johnson and Johnson, as an advisor to Celgene, and as a member of the Scientific Advisory Council to the No Stomach for Cancer Foundation. H.K. reviewed the manuscript; he is a scientific contributor and Vice President at Astex Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials.